Julia Fehniger, MD, a third-year oncology fellow at NYU Langone Health’s Perlmutter Cancer Center, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

The PARP inhibitors have been generally well tolerated, and most patients like the convenience of the oral drug, says Fehniger. She has seen nice responses with the class of drugs, and it provides patients with the ability to stay off chemotherapy for a period of time.

Fehniger says that it is exciting to think about expanding the use of PARP inhibitors to other tumor types in ways physicians wouldn’t have expected.

Videos

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Julia Fehniger, MD

Articles

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers